IDF No 2765 A Method for Synthesizing Toxic-Free Spherical-Shaped Bioglass Nanoparticles by a Microfluidic Device

System for Handling Rehabilitation Strategy Training for Subject

Technology Category/Market

Category- Assistive, Test Equipment & Design Manufacturing/ Others

Industry Classification:

Medical Devices, Rehabilitation Technology, Assistive Technology, Physical Therapy, and Healthcare Solutions

Applications:

Rehabilitation Strategy for Stroke Patients- targeting recovery in both normal and stroke conditions; specific tasks such as congruent aiming, incongruent aiming, and equidistant aiming tasks

Market report:

The global stroke rehabilitation market was valued at USD 144.9 Billion in 2023, and projected to grow to USD 376 Billion by 2033 with a CAGR of 9.2%

Image Gallery

Problem Statement

  • Stroke, leading to upper extremity dysfunction, causes motor impairments such as hemiparesis, making everyday tasks like reaching and grasping difficult for patients.
  • Existing rehabilitation approaches, including CIMT and bimanual training, have conflicting strategies, making it difficult to determine the best treatment for individual stroke patients.
  • Recovery depends on factors like initial severity and brain reorganization, with some patients showing progress years after the stroke, complicating the prognosis.
  • There is need for a more effective rehabilitation method that addresses the contradictions in current treatments and improves patient outcomes.

Technology

  • The invention employs two semi-independent systems with interconnected motor-cortical and cortico-basal ganglia loops to facilitate customized rehabilitation strategies for upper extremity hemiparesis.
  • Utilizes Self-Organizing Maps (SOM) and Continuous Attractor Neural Networks (CANN) for dynamic motor cortex representation and integration of multiple sensory and feedback inputs.
  • Supports unimanual, bimanual, and Constraint-Induced Movement Therapy (CIMT) for rehabilitation, optimized based on stroke severity and lesion size.
  • Evaluates rehabilitation efficacy using metrics like Peak Resultant Velocity (PRV) and reaching error under varying lesion conditions and task complexities
  • Simulates real-world reaching tasks and recovery processes through a two-link arm model controlled by neural feedback, enabling insights into stroke recovery and therapy optimization

Key Features/Value Proposition

  • Simulates human motor control more realistically with detailed cortico-basal ganglia interactions than existing models.
  • Adapts strategies to lesion size and task complexity, unlike rigid conventional rehabilitation systems.
  • Tracks metrics like PRV and reaching error, offering objective evaluations instead of subjective observations.
  • Addresses both immediate and delayed stroke rehabilitation, supporting comprehensive therapy plans.
  • Focuses on complex bimanual tasks, enabling effective rehabilitation for everyday functional movements.
Questions about this Technology?

Contact for Licensing

Research Lab

Prof. Srinivasa Chakravarthy V

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref 1745
  • IN 507924 Patent Granted

Technology Readiness Level

TRL 2

Technology Concept Formulated

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2394 3D Printed Three-layered Polymer Scaffold for Periodontal Regeneration, Method for Preparing the Scaffold

3D Printed Three-layered Polymer Scaffold for Periodontal Regeneration, Method for Preparing the Scaffold

Technology Category/Market

Technology: 3d Printed Three-layered polymer scaffold for periodontal regeneration, method for preparing the scaffold

Category: Biotechnology & Genetic Engineering

Industry: Biomedical

Application: Osteochondral tissue engineering to facilitate multi tissue regenerations.

Market: The global market size is USD 1.55 trillion in 2023 and is projected to grow at a CAGR of 13.96% from 2024 to 2030.

Image Gallery

Problem Statement

  • Periodontitis is a prevalent non-communicable disease affecting teeth, cementum, bone, and periodontal ligament.
  • Current treatments include plaque elimination, controlling inflammation, and periodontal surgeries.
  • Regeneration of periodontal structure requires quality regeneration of all three tissues, in the right quantity, and in the same architecture as native tissue.
  • 3D printing technology has gained popularity in dentistry for creating multi-layered scaffolds, but it does not fully mimic the native periodontal complex and does not guide fiber orientation or anchoring.
  • Various designs have been proposed for regeneration.

Technology

3D Printed Three-Layer Polymer Scaffold

  • First scaffold: Vertical polymer scaffold containing angular tubes.
  • Second scaffold: Continuous slots to glide over other end of angular tubes.
  • Angular tubes have wide pores for fibroblast migration.
  • Both scaffolds contain polymers from polylactic acid (PLA) and polyethylene terephthalate glycol (PET-G).
  • Printing first and second scaffolds to a platform temperature of 550C to 700C.

Key Features/Value Proposition

Layer arrangement:

  • First, Second, Third layers.

First scaffold:

  • Vertical scaffold with angular tubes.
  • Vertical scaffold: 6mm x 6mmx 0.3mm to 12mmx 12mmx0.6mm.
  • Polymer weight: First scaffold: 255mg to 265mg;

Second scaffold:

  • Continuous slots to glide over the first scaffold’s angular tubes.
  • Polymer weight: Second scaffold: 75mg to 85mg.
  • Second scaffold: 6.5mm x 6mmx 0.3mm to 13mmx 12mmx0.6mm.

Angular tubes:

  • Wide pores for fibroblast migration and population.
  • Pore diameters ranging from 0.1mm to 0.2mm.
  • Equal spacing of angular tubes on vertical scaffold.
  • Angles: 55°-70°, 90°, 100°-120°
  • Angled tubes: 2mm to 4mm, outer diameter 1mm to 2mm, inner diameter 0.8 mm to 1.6mm.

Coating:

  • Collagen, poly-L-lysine, hydrogel gelatin methacryloyl (GelMA), and fibronectin.

3D Printing Method:

  • Step (a) printed using a 3D printer at nozzle temperature between 1950°C and 2400°C.
  • Step includes coating scaffold with components from collagen, poly-L-lysine, hydrogel gelatin methacryloyl (GelMA), and fibronectin.

Technique used:

  • Fused deposition modeling (FDM).

Coating Scaffold with Components:

  • Collagen, poly-L-lysine, Hydrogel Gelatin Methacryloyl (GelMA), and fibronectin.
Questions about this Technology?

Contact for Licensing

Research Lab

Prof. Tuhin Subhra Santra

Department of Engineering Design

Intellectual Property

  • IITM IDF Ref. 2394

  • Patent No: IN 552910

Technology Readiness Level

TRL- 3

Experimental proof of concept

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1970 Method For Preparing Calcium Lactate Nanostructures and its Applications thereof

Method For Preparing Calcium Lactate Nanostructures and its Applications thereof

Technology Category/Market

Technology: Method for Preparing Calcium Lactate Nanostructures

Category: Biotechnology & Genetic Engineering

Industry: Biomedical

Application: Drug Treatment of cancer

Market: The global market size was valued at USD 201.75 billion in 2023 and is projected to grow from USD 220.80 billion in 2024 to USD 518.25 billion by 2032, exhibiting a CAGR of 11.3% during the forecast period (2024-2032).

Image Gallery

Problem Statement

  • RNA interference (RNAi) involves introducing a short dsRNA into cells to silence gene expression.
  • The RNA-induced silencing complex (RISC) recognizes and binds to target mRNA, inhibiting translation or protein expression.
  • Essential in gene-based therapeutics for diseases like cancer, microbial infections, neurological disorders, immune-mediated diseases, and genetic disorders.
  • Challenges include safe, efficient, and economical delivery of siRNA molecules due to their anionic nature, low stability, and short half-life.
  • Need for improved calcium lactate nanostructure-based transfection reagent for effective gene silencing and therapeutic applications.

Technology

A method for preparing calcium lactate nanostructures, which are used as sirna delivery vehicles in various therapeutic applications, including rnai-based therapeutics, targeted drug delivery, and combination therapy for various disease treatments.

Key Features/Value Proposition

Preparing Calcium Lactate Nanostructures for Therapeutic Delivery:

  • Addition of calcium carbonate nanoparticles to 40% lactic acid for sonication and stirring.
  • Addition of ethanol to the syrupy liquid to form a white slurry with calcium lactate nanostructures.
  • Centrifugation at 12000 rpm for 20 minutes at 20°C to retain sediment and remove supernatant.
  • Washing of sediment with 90% ethanol for obtaining calcium lactate nanostructures.
  • Lyophilization and storage at -80°C for obtaining nanostructures.
  • Nanostructures are crystalline nanostrip, nanobelt, nanowire, nanorods with positive zeta potential.

Calcium Lactate Nanostructure Complexation Method

  • Complexes calcium lactate nanostructure with at least one siRNA.
  • Complexing occurs at pH 5-8, temperature 15-37°C, and incubation period ranging from seconds to 10 minutes.
  • CaLNS-siRNA complex inhibits target gene expression via RNA interference.

Calcium Carbonate Nanoparticle Preparation Method

  • Dissolve 250 mg sodium carbonate in 50 ml milliQ water.
  • Dissolve 300mg calcium chloride in 50 ml milliQ water under continuous sonication at 40°C.
  • Add calcium chloride to sodium carbonate under sonication for 60 minutes.
  • Wash the precipitate three times in a 4:2 milliQ water:ethanol mixture.
  • Centrifuge at 1000 rpm for 15 minutes to precipitate calcium carbonate.
  • Store freeze-dried and stored at -80°C.

“SiRNA Delivery Method”

  • Transfecting cells with CaLNS-siRNA complex.
  • Incubation of cells for 30-12 hours.
Questions about this Technology?

Contact for Licensing

Research Lab

Prof. Mukesh Doble

Department. of Biotechnology

Intellectual Property

  • IITM IDF Ref. 1970

  • Patent No: IN 549708

Technology Readiness Level

TRL-4

 Experimentally validated in Lab;

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1795 Absorption Refrigeration System with Membrane Dehumidifier (ARSMD) for Air Conditioning, Refrigeration And Freshwater

Absorption Refrigeration System with Membrane Dehumidifier (ARSMD) for Air Conditioning, Refrigeration And Freshwater.

Technology Category/Market

Technology Category: Applied Mechanics & Mechanical Engineering

Industry: Air conditioning, Refrigerator

Applications: Manufacturing of HVAC equipment.

Market report: The global refrigerator & air conditioners market size was valued at USD 211.54 billion in 2023 and is projected to grow from USD 224.24 billion in 2024 to USD 373.08 billion by 2032.

Image Gallery

Problem Statement

  • Global energy consumption is expected to rise by 28% from 2015 to 2040, with the building sector’s energy demand increasing by 1.1% annually. Air conditioning and refrigeration systems may account for over 50% of building energy use by 2050.
  • Presently, more than 90% of the air conditioning and refrigeration systems are of vapor compression refrigeration type.
  • There is a need for the system which uses low-grade energy sources like solar energy or waste heat, offer an eco-friendly alternative to the conventional compression system for humidity and temperature control.

Technology

  • Use of Membrane based Liquid Desiccant Dehumidifier : The membrane dehumidifier (109) utilizes the liquid desiccant (i.e., lithium bromide-water) to regulate the humidity of the air.
  • Energy-Efficient Heat Exchange Design: The system employs two heat exchangers (107 & 108) to recover and reuse thermal energy.
  • Fresh Water Extraction: Excess water, after condensation at the condenser, is pumped (106) out as fresh water.
  • Optimized for Hot and Humid Climates: The system is specifically optimized for hot and humid climates, where conventional air conditioning systems is not energy efficient for humidity control and often struggle maintain the indoor air quality.

Key Features/Value Proposition

  • Unlike traditional systems that only perform one function (air conditioning, refrigeration, or water generation), this invention combines all three into a single, integrated system. This reduces the need for separate equipment, saves space, and simplifies maintenance, while also offering cost savings through energy efficiency.
  • The use of a membrane dehumidifier eliminates the risk of air entering the solution circuit, which is a common issue in traditional desiccant systems that can cause corrosion and performance decline. It ensures that the system operates reliably and maintains efficiency over a longer period.
  • The optimal application of internal heat exchangers improves the overall coefficient of performance (COP) by recycling thermal energy, which is not typically done in conventional systems. This results in lower energy consumption and operational costs.
  • Many existing systems focus only on cooling or refrigeration, while this invention adds the capability of fresh water production. The system recycles the condensate from the dehumidifier, converting it into fresh water.
  • Traditional air conditioning systems tend to lose efficiency in humid and hot environments. This system is specifically designed to overcome the challenges of hot, humid climates by utilizing desiccant based humidity control.
Questions about this Technology?

Contact for Licensing

Research Lab

Prof. M.P.Maiya

Department of Mechanical Engineering

Prof. Shaligram Tiwari

Department of Mechanical Engineering

Intellectual Property

  • IITM IDF Ref 1795
  • IN 475440 Patent Granted

Technology Readiness Level

TRL 3

Experimental proof of concept

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1718 System and Method for Encoding and Decoding Ethnic Data into Genetic Codes

System and Method for Encoding and Decoding Ethnic Data Into Genetic Codes

Technology Category/Market

Technology: Data Science & Database System

Industry: Archives, Traditional Knowledge Database,Database management Government & Defense, Banking, Data security, Manufacturing of data storage devices/ memory devices.

Applications: Storage of ethnic data, Securing national level official data such as government and defense data, archaeological data, defense data etc., can also be used to create experience systems of mythology within virtual reality environments generated by the computer system

Market: The global DNA digital data storage market is projected to expand at a CAGR of 64.4% during period from 2022 to 2035.

Image Gallery

Problem Statement

  • According to UNESCO’s World Atlas of Languages, Sanskrit is an endangered language. Thus, ethnic data  such  as  mantras,  slogans, verses  etc  are  at  a  risk  of  being  lost  to  future generations
  • Conventional methods of  preservation  of  ethnic data   include cultural practices such as human memory or manuscripts based instructions in Veda paathashalas and electronic storage in DVDs, hard-drives etc.
  • However, traditional cultural practices have substantially eroded due to foreign invasions and lingering effects of cultural colonialism while conventional electronic storage devices can be hacked and are prone to damage over longer periods of time.
  • There is a need to utilize DNA based encoding and decoding techniques to aid the conversion of ethnic data into genetic code to enable storage of data in a highly encrypted format for longer timespans

Technology

  • A newly developed VKRSV encoding module for encoding the ethnic data into a genetic code stores the ethnic data securely for longer time periods
  • The encoded data can be stored as a DNA nucleotide sequence having A, T, G, C format in order to hide data in an original format.
  • the encoded mantra as a DNA nucleotide sequence form (304 bps and 340 bps) is cloned into a pET-28a + plasmid vector of 5.369 4 kbps size
  • The cloned plasmid DNA is transformed into a bacterial system (E.coli) and stored at -80⁰C for long-term storage. This data can be retrieved using the same VKRSV decoding module

Key Features/Value Proposition

  • As one gram of DNA carries 108 TB (TeraBytes) of data, the system can be used to store large amounts of data in a highly secure and compact manner. Whereas, one gram of silicon chip carries only 16 MB of data.
  • The glycerol stocks of bacterial culture containing data can be stored in liquid nitrogen for a thousand years. Whereas conventional storage methods may get corrupted when stored for long periods of time.
  • The processing time for encryption and decryption of data using DNA cryptography is mush faster when compared to conventional cryptography methods.
Questions about this Technology?

Contact for Licensing

Research Lab

Prof. Rama S Verma

Department of Biotechnology,

Prof. Kamakoti V

Department of Computer Science & Engineering,

 

Intellectual Property

  • IITM IDF Ref. 1718

  • IN 475673 Patent Granted

  • PCT Application No: PCT/IN2019/000025

Technology Readiness Level

TRL 6

Technology demonstrated in relevant environment

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1083 An Optimized Bioprocess for Enhancing Camptothecin Yield from Endophytes

An Optimized Bioprocess for Enhancing Camptothecin Yield from Endophytes

Categories for this Invention

Category – Biotechnology and Bioprocessing

Applications – Pharmaceutical, Biopharmaceutical R&D,

Industry – Pharmaceuticals and Biotechnology

Market – Global bioprocess technology market size is expected to reach $45.04 Bn by 2028 at a rate of 15.1% CAGR.

Image Gallery

Problem Statement

  • Existing methods for Camptothecin (CPT) production from plant sources are inefficient, yielding low quantities, and are economically unfeasible.
  • Camptothecin production by endophytic fungi, like Fusarium solani, decreases over time, potentially due to the absence of host stimuli in culture media.
  • There is a demand for an optimized in vitro bioprocess to enhance Camptothecin production from endophytes, addressing the challenges of low yield and production attenuation.

Technology

  • Enhanced Camptothecin Yield: The optimized bioprocess increases Camptothecin (CPT) production by over 60% from Fusarium solani using exogenous agents like ethanol and extracts of Catharanthus roseus.
  • Efficient Extraction Process: Camptothecin is efficiently extracted from the dry biomass through a sonication and solvent extraction method, followed by quantitative analysis using RP-HPLC.
  • Cost-Effective and Scalable: The process uses readily available elicitors and growth medium components, making it a cost-effective and robust method for large-scale CPT production.

Key Features / Value Proposition

1.Increased Yield Efficiency:

  • Over 60% enhanced Camptothecin (CPT) production through optimized bioprocesses using Fusarium solani.

2. Cost-Effective Production:

  • Utilizes readily available exogenous agents and growth mediums, reducing overall production costs.

3. Scalability Potential:

  • The robust and scalable process is suitable for large-scale industrial applications, meeting growing demand for CPT.

4. Enhanced Extraction Method:

  • Efficient sonication and solvent extraction protocol ensures high purity and yield of Camptothecin.

5. Versatile Growth Medium:

  • Employs Potato Dextrose Broth (PDB) for optimal growth and metabolite production in endophytes.

6. Reliable Quantitative Analysis:

  • Accurate quantification of CPT using RP-HPLC, ensuring consistent product quality and potency.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Smita Srivastava

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 1083
  • IN 365151 – Patent Granted
  • NBA/IPR/Appl/ 3514/20-21/2571

Technology Readiness Level

TRL – 4

Technology validated in lab scale.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 976 A Bioreactor for Tissue Engineering

A Bioreactor for Tissue Engineering

Categories for this Invention

Category – Advanced Biomanufacturing

Applications – Tissue Engineering, Cell-Based Therapies, Biomaterials Fabrication

Industry – Biotechnology and Pharmaceutical

Market – Bioreactor Market, valued at USD 5.31 billion in 2024, is projected to reach USD 7.60 billion by 2029, growing at a CAGR of 7.45%

Image Gallery

Problem Statement

  • Traditional bioreactors require intricate designs or sensors to effectively detect and optimize cell and tissue culture.
  • There is a demand for bioreactors that can achieve tissue growth with fewer complexities, particularly through the application of physiological flows and stresses.
  • Existing bioreactors lack the capability to provide optimal environments for diverse tissue, organ, or cell production with the required functionality.

Technology

  • Controlled Environment for Cell Growth: The bioreactor is designed with at least two chambers, equipped with sensors and a controller to monitor and regulate conditions like temperature, pH, and gas concentration, enhancing cell proliferation and differentiation with or without scaffolds.
  • Electromechanical Drive Mechanism: The bioreactor features an electromechanical system that applies magnetic fields and shear stress to the cells, promoting cell growth and maturation, with adjustable inlet/outlet ports for precise environmental control.
  • Advanced Monitoring and Agitation: The system includes a conical platform and membrane filters to manage cell transfer between chambers, while integrated sensors provide feedback to maintain optimal conditions, ensuring high-quality tissue or cell culture production.

Key Features / Value Proposition

1. Enhanced Cell Growth:

  • Optimized for both scaffold-based and scaffold-free cell culture, boosting cell proliferation and differentiation rates.

2. Precision Environmental Control:

  • Integrated sensors and controllers regulate critical factors like temperature, pH, and gas levels, ensuring consistent and reproducible cell culture conditions.

3. Shear Stress and Magnetic Field Application

  • Electromechanical drive mechanism imparts controlled shear stress and magnetic fields, enhancing cellular responses and tissue maturation.

4. Scalable Dual-Chamber Design:

  • Modular bioreactor with separated chambers allows for distinct stages of cell culture, from initial growth to final maturation.

5. Real-Time Monitoring:

  • Advanced sensors, including temperature, osmolality, and pH, provide continuous feedback, enabling precise adjustments to the cell culture environment.

6. Customizable and Versatile:

  • Adaptable configuration with replaceable components like membranes and heat exchangers, suitable for various cell types and research applications.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Venkatesh Balasubramanian

Prof. Soma Guhathakurta

Department of Engineering Design

Intellectual Property

  • IITM IDF Ref. 976
  • IN 510399 – Patent Granted

Technology Readiness Level

TRL – 5

Technology validated in relevant environment.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2202 Automated Coverslipper for Large Format Slides with Switchable Compatibility to Handle Multi Format Slides

Automated Coverslipper for Large Format Slides with Switchable Compatibility to Handle Multi Format Slides

Categories for this Invention

Technology: Automated coverslipper to handle multi format slides

Category: Biotechnology & Genetic Engineering

Industry: Biomedical

Application: Tissue engineering

Market: The global market size was valued at USD 184.5 Million in 2023 and is projected to reach USD 259.2 Million by 2030, growing at a CAGR of 5.1% during the forecast period 2024-2030.

Image Gallery

Problem Statement

  • Periodontitis is an inflammation caused by biofilms, causing tooth loss and edentulism.
  • Traditional treatments involve guided tissue regeneration using periodontal membranes.
  • Graphene, with its large surface area, high thermal and electrical conductivity, and superior mechanical properties, has been used in engineering and biomedical fields.
  • Recent developments in 3D graphene foams (GFs) have been developed to avoid agglomeration and facilitate uniform distributions, making them ideal for scaffold preparation in tissue engineering and regenerative medicine.
  • However, there is a gap in understanding 3-D organization in multicellular tissue formation and functional restoration on scaffolds.

Technology

  • A coverslipping system consists of a coverslipper device on a frame that moves from one or more zones.
  • A coverslipping system consists of a coverslipper device on a frame that moves from one or more zones.
  • The dispensation zone dispenses a mountant medium, and the slip pick-up zone picks up the coverslips from the tray.
  • The coverslipping zone positions the platform in the coverslipping zone, and the picked coverslip is mounted over the slide.
  • The output zone transports the processed cover slip slide and inserts it into a tray, which is moved up and down to accommodate the next processed slide.

Key Features / Value Proposition

Coverslipper Device Overview:

  • Processes large format slides of 6” X 8” and 5” X 7”, and can be customized to smaller sizes.
  • Features a slide tray with stained slides inserted into grooves for easy pick-up. Uses a wedge-shaped nozzle to uniformly dispense mountant medium over the slide.
  • Controlled by a dedicated algorithm for accurate and uniform placement and air bubble prevention.
  • Composed of a vertical plate, a first curved plate, and a second curved plate.
  • Rotates the second curved plate along a predefined path, allowing vacuum suction cups to lift the cover slip.
  • Achieves a unique locus of motion to prevent air pockets and bubbles below the cover slip.The rack mimics human ankle motion between Dorsiflexion and Plantarflexion positions.

Uses and Applications:

  • Prevents contact between the microscope’s objective lens and the specimen.
  • Provides an even thickness (in wet mounts) for viewing depth.
  • Viewing enhancement as the specimen is flattened.
  • Deceleration of evaporation from the sample, both in wet and dry mounted slides.
  • Permanent affixation for long term and repeated use of Permanent Specimens.

Large Format Specimen Protection and Storage:

  • Enables long-term preservation and storage of large format specimens.
  • Economizes cover-slipping process through indigenous algorithms
  • Versatile, supporting multiple slide sizes, a unique feature not found anywhere else
  • Supports cover-slipping of large quantities of slides, like adult human brain sections.
  • Processes large format cover-slips, a unique feature not developed globally.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Jayaraj Joseph

Prof. Mohanasankar sivaprakasam

Department of Electrical Engineering

Intellectual Property

  • IITM IDF Ref. 2202

  • Patent No: IN 546396

  • PCT/IN2022/050598

Technology Readiness Level

TRL- 4

Experimentally validated in Lab

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2055 Functionally Gradient 3-layered Graphene Foam-polymer Scaffold for Periodontal Regeneration

Functionally Gradient 3-layered Graphene Foam-polymer Scaffold for Periodontal Regeneration

Categories for this Invention

Technology: Graphene foam – polymer scaffold

Category: Biotechnology & Genetic Engineering

Industry: Bio Medical Engineering

Application: Periodontal regeneration,bone and bone related tissue  regeneration

Market: The global market size was grown rapidly in recent years. It will grow from $282.19 billion in 2023 to $320.38 billion in 2024 at a compound annual growth rate (CAGR) of 13.5%.

Image Gallery

Problem Statement

  • Periodontitis is an inflammation caused by biofilms, causing tooth loss and edentulism.
  • Traditional treatments involve guided tissue regeneration using periodontal membranes.
  • Graphene, with its large surface area, high thermal and electrical conductivity, and superior mechanical properties, has been used in engineering and biomedical fields.
  • Recent developments in 3D graphene foams (GFs) have been developed to avoid agglomeration and facilitate uniform distributions, making them ideal for scaffold preparation in tissue engineering and regenerative medicine.
  • However, there is a gap in understanding 3-D organization in multicellular tissue formation and functional restoration on scaffolds.

Technology

  • “Functionally Gradient 3-Layer Graphene Foam Polymer Scaffold for Periodontal Regeneration“
  • Created with three distinct layers.
  • Layers prepared with distinct reinforcement, morphology, porosity, and mechanical strength.
  • Combines spin coating and vacuum drying sequentially.

Key Features / Value Proposition

Graphene Foam Creation:

  • Three distinct layers with unique reinforcement, morphology, porosity, and mechanical strength.

Graphene Foam Surface Coating:

  • Diluted PCL solution (4% w/v) for structural stability.
  • Dip-coated and vacuum dried.

Dip-Coated GF Structural Similarity:

  • Shows structural similarity to middle periodontal ligaments.
  • Provides directional cell migration cues.

Cementum Side Preparation:

  • Reinforcement with highly concentrated PCL.
  • Spin-coating for reinforcement.

“PVA Coating Process”:

  • Water-soluble polymer coated.
  • Spin-coating up to desired middle layer thickness.

The last layer is prepared with PCL (15%w/v)-HA solution:

  • to mimic the bone layer.

Adjusting Layer Thickness and Porosity:

  • Manipulating spin coating duration.
  • Adjusting layer porosity with polymer concentration and vacuum drying parameters.

Reinforcing Polymers for Tissue Regeneration:

  • Useful for other tissue regeneration applications.

Periodontitis Treatment Overview:

  • Regeneration of cementum, periodontal ligament, bone.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Tuhin Subra Santra

Department of Engineering Design

Intellectual Property

  • IITM IDF Ref.2055

  • Patent No: IN 545761

Technology Readiness Level

TRL- 3

Experimental Proof of concept

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2419 In-vitro Method for Intracellular Delivery of Biomolecule in Three-dimensional (3D) Cell Culture Spheroids

In-vitro Method for Intracellular Delivery of Biomolecule in Three-dimensional (3D) Cell Culture Spheroids

Categories for this Invention

Category: Biotechnology & Genetic Engineering

Industry: Biotechnology and Pharmaceutical

Application: Intracellular Delivery System, Dye, Plasmid, Enzymes, Cellular Therapy, Diagnostics, Drug Development, Disease Modeling

Market: The global 3D Cell Culture Market was valued at $1.9 Billion in 2024 and is expected to reach $4.6 Billion by 2033, at 11.3% CAGR during forecast period.

Image Gallery

Problem Statement

  • Existing methods for delivering biomolecules in 3D cell culture spheroids, suffer from low efficiency and limited penetration depth.
  • Traditional delivery techniques face difficulties in achieving high transfection efficiency while maintaining cell viability, particularly in complex 3D cell culture models.
  • The current methods often result in inadequate delivery, which hampers the accuracy and relevance of experimental outcomes.
  • Optimizing laser power, exposure time, and spot size is crucial for intracellular delivery. Deviation leads to suboptimal results & compromise experimental integrity.
  • Hence, there is a need for a method to overcome limitations of intracellular delivery techniques of biomolecules in 3D cell culture spheroids.

Technology

The technology disclosure outlines an innovative method for the intracellular delivery of biomolecules within three-dimensional (3D) cell culture spheroids. Cells are cultured in a 96-well microplate to form 3D cell culture spheroids, providing a more physiologically relevant model compared to traditional 2D culture.

Key Features / Value Proposition

  • Achieves high efficiency intracellular delivery (80%-91%) within 3D cell culture spheroids.
  • Compatible with various cell types, including primary cells and cancer cell lines.
  • Ensures minimal cell damage and Maintains high viability with optimized laser parameters.
  • Represents advancement in the intracellular delivery technique.
  • Utilizes innovative gold nanostar-mediated delivery for enhanced specificity.
  • Provides physiologically relevant results by mimicking in vivo tumor microenvironments.
  • Offers biocompatibility and safety with gold nanostars and infrared diode lasers.
  • Cost-effective and user-friendly, utilizing common laboratory equipment and reagents.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Tuhin Subhra Santra

Department of Engineering Design

Intellectual Property

  • IITM IDF No: 2419

  • IN Patent Grant No: 486848

Technology Readiness Level

TRL – 4

Experimentally validated in lab.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1966 2D Substrate Protein Micropatterning Process for Cell Alignment

2D Substrate Protein Micropatterning Process for Cell Alignment

Categories for this Invention

Technology: Process for fabricating a SU 3D structure on a silicon substrate

Category: Precise single cell analysis

Industry: Biomedical industry

Application: Tissue engineering ,nanotechnology

Market: The global market size was estimated to be worth $3.5 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028

Image Gallery

Problem Statement

  • Cells interact with the Extracellular Matrix (ECM) through receptors like Integrin, sensing mechanical and chemical stimuli.
  • Organs have unique structures and alignments, making 2D and 3D patterned microenvironments crucial for cell growth in tissue-engineered organ substitutes.
  • Tissue engineering techniques create customized microenvironments for cell alignment, varying from organ to organ.
  • Techniques include electromagnetic fields, electrophoretic force, nanofiber scaffolds, 3D gels, and microstructure substrates.
  • There is no techniques using chemical stimulus to achieve cell affinity and align cells on a substrate.
  • The need for an improved 2D substrate protein micropatterning process exists to align cells in a specific pattern by providing chemical stimulus, achieving cell affinity to the specific stimulus.

Technology

2D Substrate Protein Micropatterning Process:

  • Forming mold using SU8 3D structure on silicon substrate.
  • Casting polydimethylsiloxane (PDMS) stamps using SU8 3D structure.
  • Cleaning silicon substrate with Piranha solution at 80°C for 10 minutes and washing in deionized water.
  • Dried with nitrogen blow, kept at 120 °C for 5 minutes for dehydration in order to form the SU8 3D structure
  • Casting PDMS pillar array using mold.
  • Aligning cells in a specific pattern using 2D substrate.
  • Achieving cell affinity to specific chemical stimulus

Key Features / Value Proposition

Structure

  • A mold is formed using a SU8 3D structure on a silicon substrate for casting polydimethylsiloxane (PDMS) stamps.
  • The SU8 3005 (Micro chemical) is selected for making the 3D mold.
  • The SU8 3D structure is spin-coated, soft-baked, patterned, hard-baked, and developed in a SU8 developer.

Cell Alignment

  • Innovative Cell Alignment Process in Extra Cellular Matrix (ECM) Structure
  • Improved 2D substrate protein micropatterning process for cell alignment.

Cell affinity

  • Provides chemical stimulus to cells, enabling them to align in a specific pattern and achieve cell affinity.

Toxicity

  • The process is nontoxic, easy to implement, and can pattern heterogeneous cell lines.

Performance

  • Efficient analysis of genetic disorder for the patient at a single cell level
  • Precise genome and transcriptome analysis at the single cell level, provide functional consequence of mutation and copy number variation of cells

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Tuhin Subhra Santra

Department of Engineering Design

Intellectual Property

  • IITM IDF Ref. 1966

  • Patent No: IN 486480

Technology Readiness Level

TRL- 4

Experimentally validated in Lab

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2271 Synthesis of Toxic-free Star Shaped Gold Nanostructures using Microfluidics and its usage in Intracellular Delivery

Synthesis of Toxic-free Star Shaped Gold Nanostructures using Microfluidics and its usage in Intracellular Delivery

Categories for this Invention

Technology: Toxic-free star shaped gold nanostructures

Category: Micro & Nano Technologies

Industry: Bio-Micro/Nano, Biomedical Engineering

Application: Intracellular delivery using photoporation

Market: The global market size of nanomaterials in personalized medicine is expected to increase from $346.7 billion in 2023 to $592.0 billion by the end of 2028, with a compound annual growth rate (CAGR) of 11.3% during the forecast period of    2023-2028.

Image Gallery

Problem Statement

  • Anisotropic gold nanoparticles, with near-infrared tunability, are useful in cellular transfection and biomedical applications, targeting cancer cells and causing thermomechanical damage through laser radiation.
  • Gold nanoparticles are created through chemical reduction using reducing agents like trisodium citrate, sodium borohydride, or acetic acid, but controlling kinetics and producing nanostars is challenging.
  • Microfluidics technology offers high yields and low dispersion, but it requires large volumes of reagents and time.
  • A method to synthesize toxic-free star-shaped gold nanostructures is needed, requiring fewer reagents, reproducibility, cost-effectiveness, and time efficiency.

Technology

  • A method to synthesize toxic-free star shaped gold nanostructures comprising steps of

  • Preparing seed nanoparticles by adding a reducing agent into a gold precursor;

  • Diluting the seed solution prepared in step (1);

  • Adding the diluted seed solution prepared in step (2) to a first inlet of droplet microfluidic device;

  • Maintaining a low pH throughout the synthesis by feeding a strong acid through a second inlet.

  • Adding gold precursor through a third inlet;

  • Simultaneously adding ascorbic acid and silver nitrate in the next junction through a fourth and fifth inlet, respectively;

  • Adding silicone oil to the mixed reagents solution and forming aqueous droplets in oil;

  • To halt the growth process, collecting the nanostar solution in PEG solution kept at ice-cold temperature; and

  • Removing excess oil and PEG by multiple centrifugations

Key Features / Value Proposition

Application

  • Effectively useful for intracellular delivery

Toxic Content

  • Toxic-free

Shape

  • Star shaped gold nanostructures and crystalline nature

Deliver mode

  • Deliver biomolecules to the cells by light activated technique mediated by star shaped gold nanostructures

Synthesis

  • Droplet based microfluidic device can be used to synthesize star shaped gold nanoparticles in a single step without the use of any surfactant

Gold precursor

  • Tetrachloroauric acid

Strong acid is hydrochloric acid

  • Thiolated polymer
  • Poly(ethylene glycol) thiol

Reducing agent

  • Trisodium citrate for Au seed formation
  • Acetic acid for Nanostar formation

Flow rates

  • 150 to 900 µL/h to achieve the oil to aqueous phase flow rate ratio as 1 to 6.
  • At any point of synthesis, parameters can be tuned by varying the flow rate of reagents and concentration ratio.

Time efficiency

  • Au NS synthesis in microfluidic device takes only few seconds & cost-effectiveness.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Dr. Tuhin Subhra Santra

Department of Engineering Design.

Intellectual Property

  • IITM IDF Ref. 2271
  • Patent No: IN 526929

Technology Readiness Level

TRL-3

Experimental proof of concept 

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1556 Improved Perfusion Cum Compression Bioreactor System for Tissue Engineering Applications

Improved Perfusion Cum Compression Bioreactor System for Tissue Engineering Applications

Categories for this Invention

Category: Biotechnology & Genetic Engineering

Industry: Biomedical devices Manufacturing, Cell-Based Therapy Manufacturing, Vaccine Manufacturing

Application: Tissue engineering, Biomedical engineering applications and  basic science studies.

Market: The global market size of Biotechnology & Genetic Engineering was valued at USD 1.36 Billion in 2023 and projected to grow from USD 1.68 Billion in 2024 to USD 7.73 Billion by 2032, exhibiting a (CAGR) of 20.94% during the forecast period (2024 – 2032).

Image Gallery

Problem Statement

  • Bio-reactors are systems where conditions are closely controlled to  permit and induce a certain behavior in living cells or tissues.
  • The system is provided with controlled and steady flow of growth media and factors necessary for cell growth where the pH, temperature, pressure, nutrient supply and waste removal is maintained at optimum conditions.
  • Some of the types of bioreactors available are spinner flasks, rotating vessels, hollow fiber, perfusion bioreactors .
  • The present invention is an improved design of a perfusion cum compression bio-reactor for creating tissue like cartilage tissues.

Technology

Perfusion Cum Compression (PCC) bioreactor chamber was designed and fabricated with the following parts.

Compression chamber:

  • The acrylic compression chamber was slotted with 12 number of grew in two steps.
  • First slot have a larger diameter and the lower with smaller diameter which hold cell seeded scaffolds/tissue explants.
  • The first step has a cylindrical slot with diameter of 21mm and the second step has a diameter of 610mm Perpendicular to the lower grew the orifice of medium perfusion was placed.
  • The both ends of the orifice (towards and from the cell seeded scaffold/tissue explants side) the curvature is increased to make the flow of medium uniform and outer end is enabled for threaded luer connectors with silicon O-rings.
  • Silicon rubber tubing connected to the luer of the chamber pass through a peristaltic pump and then to the growth media reservoir.

Inflatable membrane O-ring:

  • The unique inflatable membrane O-ring is fabricated using silicon-rubber.
  • The one end is inflatable with compressed air and the other provisions to act as O-ring which gets suited to the larger surface diameter slot in the compression chamber.
  • The dimensions of the slots vary with the cell seeded scaffolds/tissue explants.

Compression port:

  • The compression port (20mm Dia)was designed like an inverted half head candle holder made of polypropylene or teflon or acrylic.
  • The broad end of the compression port gets suited above the Inflatable membrane O-ring.
  • On the other end of the compression port, provisions are made for connecting (barb) tubing that supply compressed air.
  • O-ring through the centre an orifice of
    3
    mm diameter was provisioned for supplying of compressed air.

Lock plate:

  • Lock plate (2mm thick) is made of stainless steel to lock the bioreactor chamber assembly intact.
  • Two plates, one at the bottom of the compression chamber and the other was suited above.
  • Using stainless steel fasteners to lock plates were locked keep the assembly intact.

Key Features / Value Proposition

  • Can be used for biomechanical forces like dynamic or static compression loading, hydrostatic pressure.
  • Growth medium of perfusion may be separately or in combination on cell seeded scaffolds/tissue explants for tissue engineering applications.
  • The compression chamber of size ratio 30x60x180 is slotted with 12 cylindrical slots.
  • Minimum loading time of the cell seeded scaffolds less than that 5-10 minutes.
  • Compact and consists of members which have dual functions.
  • vivo microenvironment by controlling the amount and type of biomechanical forces.
  • Improved bio-reactor for generating tissues like neo-cartilaginous tissues, bone tissue, liver tissues etc.
  • Easy to assemble, disassemble.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Dr. Merlin Rajesh Lal L P

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 1556

  • Patent No: IN 532512;

Technology Readiness Level

TRL – 4

Technology validated in lab scale.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1555 Method to Report and Demonstrate the Transactivation of Cyclic AMP- Induced Gene Expression

Method to Report and Demonstrate the Transactivation of Cyclic AMP- Induced Gene Expression

Categories for this Invention

Category – Synthetic Biology

Applications – Pharmaceutical, Cancer Research,

Industry  – Biotechnology and Pharmaceutical

Market – Global gene expression market is on a robust growth trajectory, with the market value expected to surge from US$14.5 billion in 2022 to an estimated US$20.8 billion by 2030, with a steady CAGR of 5.3%.

Image Gallery

Problem Statement

  • Existing methods for measuring intracellular cAMP, such as radioimmunoassays and enzyme immunoassays, are costly and require the destruction of large amounts of cells.
  • Commercially available CRE reporter systems for cAMP are indirect and prone to activation by other signaling pathways, complicating accurate measurement and interpretation.
  • There is a need for a direct method to report and demonstrate the transactivation of cAMP-induced gene expression in mammalian cells, which has led to the development of a synthetic biology-based reporter system.

Technology

  • Development of a direct method for reporting cAMP levels in mammalian cells using a synthetic construct combining the bacterial transcription regulator CRP with the transactivating factor VP16 from Herpes simplex virus.
  • The synthetic construct, CRP-VP16, binds to CRP operator sequences in the presence of cAMP, enabling concentration-dependent reporting of cAMP levels and transactivation of cAMP-induced gene expression in mammalian cell lines, independent of PKA and CREB signaling pathways.
  • This novel approach facilitates the assessment of hormone function, regulatory protein activity, and drug effects by measuring intracellular cAMP levels, offering potential applications in studying aberrant cAMP signaling in cancer cell lines with mutations affecting PKA and CREB.

Key Features / Value Proposition

Direct and Accurate Measurement:

  • Revolutionizes cAMP assessment in mammalian cells with precise, direct reporting, avoiding costly and destructive traditional methods.

Independent Transactivation:

  • Enables cAMP transactivation via synthetic CRP-VP16 construct, bypassing PKA/CREB signaling pathways for robust functionality.

Versatile Compatibility:

  • Compatible with various mammalian cell lines, including cancer cells with aberrant cAMP signaling, ensuring broad applicability.

Synthetic Biology Innovation:

  • Integrates bacterial transcriptional regulator CRP with mammalian cells, leveraging synthetic biology for advanced cellular functionality.

Simplified Workflow:

  • Streamlines experimental process by delivering construct via vectors, facilitating entry into cells for efficient implementation.

Comprehensive Applications:

  • Provides insights into hormone function, regulatory protein activity, and drug effects, expanding molecular pharmacological studies in GPCR research.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Karunagaran D

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 1555
  • IN 362101 – Patent Granted

Technology Readiness Level

TRL – 3

Proof of concept stage.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1351 Self-labeled Fusion Proteins for Ex Vivo Immunophenotyping of C-kit Receptor

Self-labeled Fusion Proteins for Ex Vivo Immunophenotyping of C-kit Receptor

Categories for this Invention

Biotechnology and Genetic Engineering | Drugs and Pharmaceutical Engineering

Industry: Healthcare, Pharma, Biotechnology

Application: Cancer diagnosis and prognosis, Immunophenotyping in leukemia and solid tumor, Allergy and autoimmune disorder diagnostics, Biomarker detection & monitoring, Drug development and personalized medicine

Market: Global Fusion Protein Market size was valued at USD 24.58 Billion in 2023 and is expected to reach USD 32.56 Billion by 2030, at a CAGR of 4.1% from 2023 to 2030.

Image Gallery

Problem Statement

  • Current methods for detecting c-kit expression in cancer, allergies, and autoimmune disorders suffer from inconsistencies due to variations in antibodies and fluorochromes used.
  • Antibody-based detection are complex, costly methods, poses immunogenicity issues.
  • Standardization of c-kit expression detection is challenging due to heterogeneous results from different labs.
  • Hence, there is a need for reliable alternative to antibody-based detection methods for accurate diagnosis and prognosis in cancer and related diseases.

Technology

The technology disclosure introduces a method for detecting expression of c-kit receptor, which is crucial in various diseases including cancer, allergies, and autoimmune disorders.

This antibody-based detection method utilizes self-labeled fusion proteins, consisting of stem cell factor (SCF) fused to SNAP-tag, allowing for covalent binding to detectable agent.

The Process Involves Following Steps:

Genetic Engineering:

  • Fusion constructs of SCF fused to a SNAP tag are cloned into a mammalian vector.

Transfection:

  • The fusion protein probe is transfected into host cells for genetic expression.

Purification:

  • The expressed fusion protein probe is purified from the transfected culture.

Labeling:

  • The probe is labeled with a detectable agent, typically benzylguanine or a derivative thereof with a fluorophore.

Key Features / Value Proposition

  • Simplicity: The production process is simpler compared to antibody production.
  • Cost-effectiveness: It is more cost-effective than antibody-based methods.
  • Specificity: The fusion proteins exhibit high specificity for detecting c-kit expression.
  • Stability: The SCF fused SNAP-tag is stable for extended periods, even at refrigerated temperatures.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Rama S Verma

Department of  Biotechnology

Intellectual Property

  • IITM IDF No: 1351

  • IN IP No: 415316 (Granted)

Technology Readiness Level

TRL – 4

Technology validated in lab.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 875 A Device & a Language Technology for Indian Languages

A Device & a Language Technology for Indian Languages

Categories for this Invention

Technology: Transliteration system for all the Indian languages into a single unique script called as “Bharati“; Industry: National Library & TKDL; Application Phone Apps

Market: The global language services market size id growing at a CAGR of 6.32% during 2024-2029.

Image Gallery

Problem Statement

  • In the present era, there is a need of the art to develop an easy to learn script, which is made of a small number of strokes & suitable for use in Online Handwritten Character Recognition (OHCR) systems & has a rational composition.
  • Further, there is no solutions discussed in the prior art patent literatures, & Present invention is addressed the issues efficiently.

Technology

  • Present invention describes a device & a multilingual language technology for Indian languages.
  • Further subject invention discussed about said device which is installed with an application capable of understading the script & translating it to a desired Indian language.
  • The script of the present invention is made of a small number of strokes & has a rational composition, which is easy to learn, & suitable for use in OHCR systems.

Key Features / Value Proposition

  • Present invention provides a transliteration system for all the Indian languages into a single unique script called as “Bharati“.
  • Bharati script is entirely new script, consist of minimum characters having small number of strokes, that do not belongs to any language but transliterate all the major Indian language script.
  • Thus our transliteration system includes a user interface with an application pre-programmed with Bharati characters that automatically identifies a text in an Indian language & transliterates the text.
  • The tens of thousands of characters in all the major Indian languages can be transliterated using only these Bharati characters.
  • A lot of morphologies of Bharati used are drawn from typically occurring themes in Indian alphabets systems & in English alphabets.
  • Bharati vowels are distinguished by a unique diacritic added to a common base which resembles a ‘c’ character turned leftwards, indicating the character as a pure vowel.
  • Recommended to implement the system in Traditional Knowledge Digital Library & other National Indian Libraries.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. V Srinivasa Chakravarthy,

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 875

  • Patent No:377318;

Technology Readiness Level

TRL-4

Proof of concept tested in Lab;

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1862 Process For Production Of High Molecular Weight Hyaluronan In A Recombinant Lactococcus Lactis Using Acetate Co-utilization Fed-batch Strategy

Process For Production Of High Molecular Weight Hyaluronan In A Recombinant Lactococcus Lactis Using Acetate Co-utilization Fed-batch Strategy

Categories for this Invention

Biotechnology & Genetic Engineering

Industry: Pharmaceuticals, Biomedical Products

Applications: Advanced Materials, Food & Drugs, Medical & Surgical, Medical-grade hyaluronic acid (HA) for visco-supplementation in osteoarthritis treatment, High MWHA for enhanced stability in eye surgeries, HA in wound healing applications, HA for anti-cancer drug delivery, Cosmetic applications utilizing low molecular weight HA.

Market: The Global Hyaluronic Acid Market was estimated at USD 1.1 Bn in 2021, is expected to reach around USD 2.60 Bn by 2030, growing at 8% CAGR from 2022 to 2030.

Image Gallery

Problem Statement

  • Current methods for hyaluronic acid (HA) production suffer from limitations like lower molecular weights, hindering effectiveness in biomedical applications.
  • Existing metabolic engineering approaches focus on enzyme-coding genes but often overlook crucial cofactors, impacting HA production in recombinant strains like L. lactis.
  • Traditional methods and past engineering efforts left an unmet need for higher molecular weight HA demand in medical applications.
  • Utilization of cost-effective acetate in HA production faces challenges, there is a critical gap in exploring cofactor engineering strategies to enhance HA production and achieve greater stability for biomedical uses.
  • Hence, there lies a need for enhancing MWHA production, using process strategies, especially with acetate supplementation and co-utilization.
  • The instant invention discloses a process for producing higher MWHA (3.4 MDa) with high yield by anaerobic microbial fermentation with process control parameters.

Technology

  • Utilization of a genetically engineered strain of Lactococcus lactis, named MKG6, expressing key genes from Streptococcus zooepidemicus for enhanced HA biosynthesis.
  • Strategically manipulating metabolic pathways (FIG 2) and introduces acetate co-utilization to optimize cofactors like acetyl-CoA, crucial for HA production.
  • Incorporating batch acetate pulse feed, batch process with acetate and glucose pulse feed, constant fed-batch, and pH feedback fed-batch strategies for controlled & sustained HA production.
  • The invention introduces a process for producing hyaluronic acid (HA) with a consistently high molecular weight (3.4 MDa) through anaerobic microbial fermentation. The process comprises:

Key Features / Value Proposition

User perspective:

  • Enhanced Product Efficacy, Improved product Stability which is critical for reliable outcomes in medical treatments.
  • Versatile Applications, including osteoarthritis treatment, eye surgeries, wound healing, anti-cancer drug delivery, and cosmetics.
  • Biocompatibility with reduced immunogenicity and non-toxicity. Advanced Healthcare Solutions for various medical conditions.

Industrial perspective:

  • Cost-Effective Production, Breakthrough Technology achieving MWHA of 3.4 MDa.
  • Market Leadership and Bioprocessing Innovation with novel fermentation strategies.
  • Implement advanced fed-batch fermentation processes, including acetate pulse feed and pH feedback, for sustained high MWHA.

Technology perspective:

  • Employ cutting-edge genetic engineering techniques for recombinant L. lactis MKG6, enhancing HA pathway expression.
  • Strategically manipulate metabolic fluxes to maximize precursor availability and HA production. Introduce acetate co-utilization to optimize acetyl-CoA levels, a key cofactor in HA biosynthesis.
  • Leverage in-silico flux balance analysis to understand and optimize intracellular fluxes, influencing HA production.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Prabhu Rajagopal

Department of Mechanical Engineering 

Intellectual Property

  • IITM IDF No.: 1862

  •  IP No.: 412658 (Granted)

  • PCT Application No. PCT/IN2020/050447

Technology Readiness Level

TRL-4

Validated in Laboratory

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2025 A Method to Derive Functional Hepatocytes

A Method to Derive Functional Hepatocytes

Categories for this Invention

Regenerative Medicine & Stem Cell Therapy.

Applications– Liver Failure Treatment, InVitro Drug Testing, Biomedical Research

Industry- Regenerative Medicine, Pharmaceuticals.

Market – The regenerative medicine market was valued at $12.2 billion in 2022 and is forecast to reach $40.6 billion by 2027, reflecting a  CAGR of 27.2%.

Image Gallery

Problem Statement

  • The current challenges in treating liver failure revolve around the limitations of liver and hepatocyte transplantation, including donor availability and high costs.
  • Stem cell-based approaches, particularly with mesenchymal stem cells (MSCs), hold promise, but existing differentiation protocols are expensive and time-intensive.
  • Moreover, reliance on a single small molecule for differentiation raises concerns about long-term efficacy.
  • Despite the advantageous immunomodulatory properties of MSCs, their potential in clinical settings remains underexplored due to extended differentiation times and cost considerations.
  • There is a critical need for a more efficient, cost-effective, and technology-driven method to derive functional hepatocytes from MSCs for effective liver failure treatment.

Technology

The present invention relates to a method for deriving functional hepatocytes from mesenchymal stem cells using a combination of small molecules.

  • Accelerated Differentiation Process: Unlike traditional methods requiring 28 days, the present invention achieves hepatocyte differentiation in just 14 days. This shortened duration enhances the practicality and efficiency of the process for clinical applications.
  • Consistent and Defined Media Composition: The chemically defined composition of the differentiation media eliminates batch-to-batch variation, ensuring a standardized and clinically viable protocol for deriving functional hepatocytes.
  • Safe and Clinically Relevant Source: Utilizing mesenchymal stem cells, which are already employed in clinical settings, ensures the safety and relevance of the derived hepatocytes for therapeutic use in liver failure treatment and in vitro drug testing.

Key Features / Value Proposition

Cost Efficiency and Affordability:

  • The chemical method significantly reduces costs compared to growth factor-based approaches, offering an economically viable solution for hepatocyte differentiation

Rapid Differentiation Timeline:

  • Achieves functional hepatocyte differentiation in just 14 days, providing a time-efficient alternative to the conventional 28-day duration associated with growth factor-based methods.

Consistent and Defined Media Composition:

  • The chemically defined media ensures consistency, eliminating batch-to-batch variation and providing a standardized protocol for deriving functional hepatocytes.

Clinical Viability and Safety:

  • Derives hepatocytes from mesenchymal stem cells, already used in clinical settings, ensuring safety and making it a suitable candidate for clinical applications in liver failure treatment.

Alternative to Growth Factors:

  • Overcomes the need for growth factors, reducing the overall complexity and cost of the differentiation process for functional hepatocytes.

Versatile Applications:

  • Extends beyond liver failure treatment to include potential applications in cell-based therapeutics and in vitro drug testing, enhancing its versatility and relevance across multiple domains.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Rama S Verma,

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 2025
  • IN 411233 – Patent Granted

Technology Readiness Level

TRL – 4

Technology validated in lab scale.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 1619 Method for Direct Quantification of Nucleic Acids in Real Time qPCR

Method for Direct Quantification of Nucleic Acids in Real Time qPCR

Categories for this Invention

Biotechnology & Genetic Engineering

Industry: Molecular Biology, Biomedical Engg.

Application: Diagnostic, Life science Research

Market: The Global qPCR Instruments Market value is expected to grow from USD 898.98 million in 2021 to USD 1,394.75 million in 2028 at 3.4% CAGR from 2021 to 2028.

Image Gallery

Problem Statement

  • Currently quantitative PCR (qPCR) is a robust technique, widely used in biological research for studying mRNA expression, DNA copy number, allele variations etc. It has revolutionized diagnostics, offering fast, sensitive and specific detection of diseases: Dengue, Influenza A & B, Zika etc.
  • The qPCR uses two basic chemistries for quantification of amplicons of which one is cost effective but have lower specificity and the other involves fluorescent probes (FP) that use sequence-specific oligonucleotides making it expensive & successfully prevent non-specific amplification of the target.
  • Hence, there is an urgent need of the present invention that discloses the method to develop an economically feasible sequence specific probe for use in qPCR for DNA amplification.

Technology

  • The present patent technology aims to disclose a method for quantifying nucleic acids using an Aptamer-based qPCR (Apt-qPCR) probe in real-time PCR.
  • This method appears to involve utilizing a light-up dye-aptamer system, where the fluorescence increases significantly when the dye binds to its specific aptamer.

The method for direct quantification of nucleic acids in real-time qPCR, comprises:

  • using a simple and shorter Aptamer-based qPCR (Apt-qPCR) probe for quantification in real-time PCR wherein the probe uses a light-up dye-aptamer system in which the dye shows negligible fluorescence in the free state and its fluorescence increases manifold when it binds to its specific aptamer;
  • placing the aptamer 5’ upstream of one of the primers wherein the primer initially in pre-annealed form shows fluorescence as aptamer is free and single-stranded & can bind to dye;
  • performing annealing and extension step to make the aptamer double-stranded & thereby loose its 3D structure to form a double helix wherein the double helix is not specific for the dye and do not bind, therefore reducing fluorescence of the solution corresponding to each cycle of the PCR reaction.

Key Features / Value Proposition

  • This technology presents an approachable, precise, and cost-effective method for quantifying DNA amplification in real-time PCR, offering benefits across user, technical, & industrial perspectives.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Guhan Jayaraman 

Department of Biotechnology

Intellectual Property

  • IITM IDF No: 1619
  • IP No.: 393411 (Granted)
  • PCT No.: PCT/IN2018/000054
  • US Application No. 16/766,205

Technology Readiness Level

TRL 3

Experimentally validated in lab.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */

IDF No 2296 A Process for Production of Active Biomass of Viola Odorata in Bioreactors

Technology Category/ Market

Category- Bioprocessing & Biotechnology

Applications– Pharmaceuticals, Herbal Medicine and Nutraceuticals.

Industry- Pharmaceuticals and Healthcare

Market- Global bioprocessing technology market is projected to increase from $18.71 billion in 2022 to $21.74 billion in 2023, with a CAGR of 16.2%..

Image Gallery

Problem Statement

  • Viola odorata L. (Banafsha) is an endangered plant with valuable medicinal properties, but its natural propagation is challenging due to seed dormancy and specific growth requirements.
  • Natural sources of bioactive secondary metabolites from this plant are limited, with variations in composition based on environmental factors.
  • In vitro cultures offer a sustainable alternative for continuous production, but they face limitations, such as low yield and long cultivation times.
  • The need is to develop a process for enhanced biomass production of Viola odorata L. in invitro cell suspension culture, ensuring a high yield of bioactive secondary metabolites for malaria treatment.

Technology

The invention discloses a bioprocess for the production of biomass of Viola odorata L comprising:

  • Preparation of inoculum comprising suspending in vitro developed callus, in growth medium(A) and growing at optimal culture conditions to form cell suspension culture, from which cells were isolated and used as inoculum;
  • Inoculating the inoculum at a specific density in optimized growth medium(C) contained in bioreactor and culturing the inoculum for 12-50 days under optimal conditions of temperature, pH, light intensity, agitation, aeration and photoperiod in the presence of anti-foaming agent to form biomass;
  • Harvesting the biomass after 12-50 days by filtering the contents of bioreactor through filter paper under vacuum.

The said bioprocess for the production of biomass of Viola odorata L, the bioprocess further comprises:

  • Washing the harvested biomass with distilled water to form washed biomass;
  • Lyophilizing the washed biomass to form lyophilized biomass;
  • Homogenizing the lyophilized biomass by macerating in aqueous ethanol (50-70%) for 6 h with intermittent shaking to form homogenized biomass;
  • Centrifuging the homogenized biomass to separate supernatant from cell debris;
  • Collecting the supernatant and lyophilizing the supernatant to form biomass extract powder;
  • Storing the biomass extract powder at -80 °C.

Key Features/ Value Proposition

Enhanced Biomass Production

  • The bioprocess optimally cultivates Viola odorata L. in bioreactors, ensuring high biomass yield for the extraction of valuable secondary metabolites.

Multi-Factor Optimization

  • Using advanced tools, the process optimizes various parameters, including temperature, pH, and growth regulators, to maximize both biomass and metabolite production.

Bioreactor Versatility

  • The choice of bioreactor design (stirrer tank, air lift, or bubble column) accommodates diverse production needs.

Operation Flexibility

  • Operate in batch, fed-batch, or continuous mode, with nutrient feeding strategies fine-tuned for efficiency.

High-Yielding Cell Lines

  • The optimized Viola odorata L. cell line VOP-4 ensures maximum biomass production.
  • Extracted metabolites exhibit potent biological activities, rivaling those from natural plant sources with applications in malaria treatment, antimicrobial, anticancer, antioxidant, and anti-inflammatory activities.
  •  

Questions about this Technology?

Contact for Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Smita Srivastava

Department of Biotechnology

Intellectual Property

  • IITM IDF Ref. 2296
  • IN 202241003520

Technology Readiness Level

TRL – 4

Technology validated in lab scale.

/* Custom Archives Functions Go Below this line */ /* Custom Archives Functions Go Above this line */